Stride Raises £4.6M for Preventive Health Platform

UK healthtech Stride has raised £4.6 million to expand a preventive-health platform combining laboratory testing, DNA and gut data with personalised guidance.

What happened

The seed financing included investors such as Arāya Ventures, Better Ventures, Morgan Stanley Inclusive & Sustainable Ventures and Innovate UK. Stride was founded by former Olympic athlete and DNAfit co-founder Andrew Steele. The company offers testing and a membership product intended to help customers track health markers over time. New capital will support additional testing products, a multi-source biological-age tool and the US launch of its StrideOne membership. Stride reports more than 16,000 customers and 85% retention among members over their first 13 months; those figures are company-reported.

Why it matters

Consumer health platforms are moving from one-off tests toward longitudinal services that combine multiple biological signals. Repeated measurements can potentially be more useful than a single snapshot, especially when tied to professional guidance.

The bigger picture

The risk is overinterpreting noisy biomarkers. Biological-age scores and personalised recommendations need careful validation to avoid giving users unwarranted confidence. Stride's long-term credibility will depend on evidence that its insights improve meaningful health decisions rather than simply increasing testing frequency.